Cargando…
Menopause hormone therapy: latest developments and clinical practice
Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317580/ https://www.ncbi.nlm.nih.gov/pubmed/30636965 http://dx.doi.org/10.7573/dic.212551 |
_version_ | 1783384756049674240 |
---|---|
author | Fait, Tomas |
author_facet | Fait, Tomas |
author_sort | Fait, Tomas |
collection | PubMed |
description | Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors. |
format | Online Article Text |
id | pubmed-6317580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioExcel Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63175802019-01-11 Menopause hormone therapy: latest developments and clinical practice Fait, Tomas Drugs Context Review Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors. BioExcel Publishing Ltd 2019-01-02 /pmc/articles/PMC6317580/ /pubmed/30636965 http://dx.doi.org/10.7573/dic.212551 Text en Copyright © 2019 Fait T. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission. |
spellingShingle | Review Fait, Tomas Menopause hormone therapy: latest developments and clinical practice |
title | Menopause hormone therapy: latest developments and clinical practice |
title_full | Menopause hormone therapy: latest developments and clinical practice |
title_fullStr | Menopause hormone therapy: latest developments and clinical practice |
title_full_unstemmed | Menopause hormone therapy: latest developments and clinical practice |
title_short | Menopause hormone therapy: latest developments and clinical practice |
title_sort | menopause hormone therapy: latest developments and clinical practice |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317580/ https://www.ncbi.nlm.nih.gov/pubmed/30636965 http://dx.doi.org/10.7573/dic.212551 |
work_keys_str_mv | AT faittomas menopausehormonetherapylatestdevelopmentsandclinicalpractice |